Reference : Efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after ...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/34842
Efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF.
English
Allez, Matthieu [Université Paris 7 > Hôpital Saint-Louis > > >]
Vermeire, Severine [> > > >]
Mozziconacci, Nicolas [Hôpital Huriez (Lille, France) > > > >]
Michetti, Pierre [> > > >]
Laharie, David [> > > >]
Louis, Edouard mailto [Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie - Relations académiques et scientifiques (Médecine) >]
Bigard, Marc-André [> > > >]
Hebuterne, Xavier [> > > >]
Treton, Xavier [> > > >]
Kohn, Anna [> > > >]
Marteau, Philippe [> > > >]
Cortot, Antoine [> > > >]
Nichita, Cristina [> > > >]
Vanassche, Gert [> > > >]
Rutgeerts, Paul [> > > >]
Lemann, Marc [> > > >]
Colombel, Jean-Frédéric [> > > >]
2009
Alimentary Pharmacology and Therapeutics
Blackwell Publishing
Yes (verified by ORBi)
International
0269-2813
1365-2036
Oxford
United Kingdom
[en] Adalimumab (ADA) and certolizumab pegol (CZP) have demonstrated efficacy in Crohn's disease (CD) patients previously treated with infliximab (IFX). Aim: To assess the efficacy and tolerability of a third anti-TNF in CD after failure of and/or intolerance to two different anti-TNF. Methods: CD patients who received ADA or CZP after loss of response and/or intolerance to two anti-TNF were included in this retrospective study. Data were collected using a standardized questionnaire. Clinical response, duration, safety and reasons for discontinuation were assessed. Results: Sixty-seven patients treated with CZP (n=40) or ADA (n=27) were included. A clinical response was observed in 41 (61%) at week 6 and 34 patients (51%) at week 20. The probability of remaining under treatment at 3 months, 6 months and 9 months was 68%, 60% and 45%, respectively. At the end of follow-up, the third anti-TNF had been stopped in 36 patients for intolerance (n=13), or failure (n=23). Two deaths were observed. Conclusion: Treatment, with a third anti-TNF (CZP or ADA) agent, of CD patients who have experienced loss of response and/or intolerance to two anti-TNF antibodies, has favorable short- and long-term efficacy and is an option to be considered in patients with no other therapeutic options.
http://hdl.handle.net/2268/34842
10.1111/j.1365-2036.2009.04130.x

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Efficacy and safety of a third anti-TNF monoclonal antibody... 2009-Al Pharm Ther.pdfAuthor preprint509.34 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.